Tumor Models Shanghai

Date: 25-Sep-18 to 27-Sep-18
Location: InterContinental Shanghai Pudong / China
Category: Healthcare & Pharmaceuticals Conferences & Trade Fairs

As we see more and more oncology products failing in the clinic there needs to be a revolution in the way we conduct our preclinical and translational research. Tumor Models Shanghai is the platform that will bring together experts from Pharma and Biotech from across Asia to discuss the vital challenges currently facing industry.

By joining us you will get access to insight into the in vivo models that are driving research forward. Including, information on the newest in vivo models, deep dives into the prediction and overcoming of resistance mechanisms, the optimisation of model and target selection rationale; and more.

Tumor Models Shanghai is the only industry-focused preclinical oncology meeting in Asia, where we will be uniting the thought-leaders and decision-makers in pharma and biotech to explore the most recent developments in the field.

As we launch this meeting in Asia for the first time, come and be a part of the conversation and hear about:

- The ways innovative biotechs like Innovent, YZY Biopharma and EpimAb are implementing in vivo models to drive development and move their pipelines forward
- The most recent updates on the models available form Crown Biosciences and The Jackson Laboratory
- Increase therapy effectiveness through effectively predicting mechanisms of resistance with case studies from companies like Abxign
- Understand how to effectively model an array of combination therapies like Innovent Biologics
- See case-study based examples of how model selection rationale has implemented into the development of novel Immuno-oncology therapies

Exhibitors

Junho Chung CSO Seoul National University College of Medicine, Bingliang Chen Chief Scientist Innovent Biologics, Kerry Blanchard Kerry Blanchard Innovent Biologics, Juan Liu Head of External Collaborations Pfizer China, Pengfei Zhou CEO YZY Biopharma, Xuan Wu Director of Biology EpimAb Biotherapeutics, Davy Ouyang Senior Director Crown Bioscience, James Keck Senior Director In Vivo Pharmacology The Jackson Laboratory, Lisa Ooi Scientific Director ASLAN Pharma, Paula Lam Head, RnD, Stem Med Pte. Ltd. Duke – NUS, Hongtao Lu CSO & Co-Founder Elpiscience, Laura Benjamin CSO & Co-Founder Oncologie International, James Yan Executive VP, Head Of Preclinical Development & Drug Safety Zai Laboratory, Li Zhen Executive Director, Antibody Discovery & Preclinical Development MABSPACE

Go to event website